|
PMID
|
Match String
|
Actual String
|
Score
|
Flanking text
|
Edited by
|
Edit
|
| 18513389 | PON2 | PON2 | 1.3 | 93 T/G, T G asp9asn asn291ser ser447term PON1 met55leu gln192arg PON2 ser311cys LDLR NcoI+/-, NcoI - CETP-631C/A, CETP-631C A -629 C/A, | |  |
| 18513389 | PON2 | PON2 | 1.3 | 8p22 paraoxonase 1 (PON1) PON1 met55leu and paraoxonase 2 (PON2) PON2 ser311cys (chromosome chromosome 7q21.3 tumor necrosis factor beta (TNF TNF | | |
| 18513389 | PON2 | PON2 | 1.3 | ALS disease appears to be confirmed PON1 met 55leu and PON2 ser311cys were chosen four times whereas PON1 gln192arg was never | | |
| 18513389 | paraoxonase 2 | paraoxonase 2 | 1.0 | imes over five experiments consisted of: peroxisome proliferator activated receptor gamma pparg pro12ala chromosome 3p25 lipoprotein lipase lpl asp9asn chromosome 8p22 paraoxonase 1 pon1 met55leu and paraoxonase 2 pon2 ser311cys chromosome 7q21.3 tumor necrosis factor beta tnf beta thr26 asn chrom 6p21.3 methylenetetrahydrofolate reductase mthfr 677 c/t chrom 1p36.3 angiotensin ii receptor type1 agtr1 1166 a/c | | |